A pivotal phase III study of ODACTRA™ in children with allergic asthma

Trial Profile

A pivotal phase III study of ODACTRA™ in children with allergic asthma

Planning
Phase of Trial: Phase III

Latest Information Update: 29 Aug 2017

At a glance

  • Drugs House dust mite allergy immunotherapy-ALK Abello (Primary)
  • Indications Allergic asthma
  • Focus Registrational; Therapeutic Use
  • Sponsors ALK-Abello
  • Most Recent Events

    • 29 Aug 2017 New trial record
    • 21 Aug 2017 According to an ALK media release, the company plans to initiate this study later in 2017 and will support approvals of ODACTRA for children with allergic asthma. The company is planning to initiate this trial in multiple locations including USA.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top